Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Efficacy, safety and tolerability of aripiprazole in bipolar disorder: An updated systematic review and meta-analysis of randomized controlled trials — Dian‐Jeng Li (2017) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Efficacy, safety and tolerability of aripiprazole in bipolar disorder: An updated systematic review and meta-analysis of randomized controlled trials
Shared by
Eduard Vieta
Efficacy, safety and tolerability of aripiprazole in bipolar disorder: An updated systematic review and meta-analysis of randomized controlled trials
Article
2017
en
Authors
+11 more
DL
Dian‐Jeng Li
PT
Ping‐Tao Tseng
BS
Brendon Stubbs
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2025
Efficacy, Safety, and Tolerability of Ferric Carboxymaltose and Iron Sucrose in Iron Deficiency Anemia: A Systematic Review and Meta- Analysis of Randomized Controlled Trials
Lokman Hekim Tanrıverdi
,
Ahmet Sarıcı
Article
2009
Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review
Konstantinos Ν. Fountoulakis
,
Eduard Vieta
Article
2021
Preventing new episodes of bipolar disorder in adults: Systematic review and meta-analysis of randomized controlled trials
Anastasiya Nestsiarovich
,
Christopher Gaudiot
,
Ross J. Baldessarini
,
Eduard Vieta
,
Yiliang Zhu
,
Mauricio Tohen
Article
2022
Efficacy and tolerability of pharmacotherapy for obsessive-compulsive personality disorder: a systematic review of randomized controlled trials
Julija Gečaitė-Stončienė
,
Taryn Williams
,
Christine Löchner
,
Jacob Hoffman
,
Dan Joseph Stein
Article
2023
Lamotrigine efficacy, safety, and tolerability for women of childbearing age with bipolar I disorder: Meta-analysis from four randomized, placebo-controlled maintenance studies
Eduard Vieta
,
Sanman Ghorpade
,
Arunangshu Biswas
,
Angshuman Sarkar
,
Abhay Phansalkar
,
James A. Cooper
Discussion(0)
No comments yet. Be the first to comment.